BRPI0606730A2 - derivados de fenil metanona 2,5-di-substituìdos como inibidores do transportador de glicina 1 (glyt-1) para o tratamento de distúbios neurológicos e neuropsiquiátricos - Google Patents

derivados de fenil metanona 2,5-di-substituìdos como inibidores do transportador de glicina 1 (glyt-1) para o tratamento de distúbios neurológicos e neuropsiquiátricos

Info

Publication number
BRPI0606730A2
BRPI0606730A2 BRPI0606730-1A BRPI0606730A BRPI0606730A2 BR PI0606730 A2 BRPI0606730 A2 BR PI0606730A2 BR PI0606730 A BRPI0606730 A BR PI0606730A BR PI0606730 A2 BRPI0606730 A2 BR PI0606730A2
Authority
BR
Brazil
Prior art keywords
glyt
treatment
inhibitors
neurological
glycine transporter
Prior art date
Application number
BRPI0606730-1A
Other languages
English (en)
Inventor
Synese Jolidon
Roger David Norcross
Emmanuel Pinard
Robert Narquizian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0606730A2 publication Critical patent/BRPI0606730A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

DERIVADOS DE FENIL METANONA 2,5-DISUBSTITUìDOS COMO INIBIDORES DO TRANSPORTADOR DE GLICINA 1 (GLYT-1) PARA O TRATAMENTO DE DISTúBIOS NEUROLóGICOS E NEUROPSIQUIáTRICOS. A presente invenção se refere a compostos da fórmula geral em que R¹ é - 0R¹', -SR¹' ou é um grupo heterocicloalquila; R¹' é alquila inferior, alquila inferior substituído por halogênio, ou é - (CH2 22)2 n2-cicIoalquiIa; R² é - S(O)2 22-alquila inferior ou - S(O)2 22NH-alquila inferior; R³ é arila ou heteroarila, os quais são não-substituidas ou substituidos por um a três substituintes, selecionados do grupo consistindo em alquila inferior, alcóxi inferior, CN, NO2 22, -C(O)-alquila inferior, -0(0)0-alquila inferior, halogênio ou alquila inferior substituída(o) por halogênio; n é 1 ou 2; m é 1 ou 2; e a sais de adição de ácido farmaceuticamente aceitáveis dos mesmos. Foi visto que os compostos de fórmula geral (1) são bons inibidores do transportador de glicina 1 (GIyT-1).
BRPI0606730-1A 2005-01-18 2006-01-10 derivados de fenil metanona 2,5-di-substituìdos como inibidores do transportador de glicina 1 (glyt-1) para o tratamento de distúbios neurológicos e neuropsiquiátricos BRPI0606730A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05100280 2005-01-18
PCT/EP2006/000127 WO2006077026A1 (en) 2005-01-18 2006-01-10 2, 5-disubstituted phenyl methanone derivatives as glycine transporter 1 (glyt-i) inhibitors for the treatment of neurological and neuropsychiatry disorders

Publications (1)

Publication Number Publication Date
BRPI0606730A2 true BRPI0606730A2 (pt) 2009-07-14

Family

ID=35985447

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606730-1A BRPI0606730A2 (pt) 2005-01-18 2006-01-10 derivados de fenil metanona 2,5-di-substituìdos como inibidores do transportador de glicina 1 (glyt-1) para o tratamento de distúbios neurológicos e neuropsiquiátricos

Country Status (14)

Country Link
US (1) US7790763B2 (pt)
EP (1) EP1843767B1 (pt)
JP (1) JP2008527016A (pt)
KR (1) KR100935256B1 (pt)
CN (1) CN101141959B (pt)
AT (1) ATE435650T1 (pt)
AU (1) AU2006207650B2 (pt)
BR (1) BRPI0606730A2 (pt)
CA (1) CA2601326A1 (pt)
DE (1) DE602006007682D1 (pt)
ES (1) ES2326833T3 (pt)
IL (1) IL184439A (pt)
MX (1) MX2007008616A (pt)
WO (1) WO2006077026A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2406085T3 (es) 2006-06-22 2013-06-05 F. Hoffmann-La Roche Ag Derivados de fenil-metanona sustituida y su empleo como inhibidores de receptores de GlyT1 y GlyT2
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
US10040759B2 (en) 2014-11-05 2018-08-07 Dart Neuroscience (Cayman) Ltd. Substituted azetidinyl compounds as GlyT1 inhibitors
WO2025198588A1 (en) * 2024-03-20 2025-09-25 Bridgene Biosciences, Inc. Preparation of compound and crystalline forms thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423847A1 (de) * 1973-05-28 1975-01-02 Ciba Geigy Ag Neue sulfamoylbenzoesaeureamide
DE2611705A1 (de) * 1976-03-18 1977-09-22 Josef Dipl Chem Dr Rer N Klosa N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel
IT1176613B (it) 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
US5393771A (en) 1993-05-12 1995-02-28 Brisol-Myers Squibb Company 4-substituted benzopyran and related compounds
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
JP4403212B2 (ja) * 1996-05-31 2010-01-27 エヌピーエス ファーマシューティカルズ インコーポレイテッド 神経障害および神経心理学的障害の治療のための製剤学的薬剤
TR200002567T2 (tr) * 1998-03-06 2000-11-21 Janssen Pharmaceutica N.V. Glisin naklini önleyiciler.
CN1291984A (zh) 1998-03-06 2001-04-18 詹森药业有限公司 甘氨酸传输抑制剂
WO2001081308A2 (en) * 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
DOP2001000189A (es) * 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
EP1554260A1 (en) 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
UA85194C2 (ru) * 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
ATE374610T1 (de) * 2003-09-09 2007-10-15 Hoffmann La Roche 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
AU2004269892B2 (en) * 2003-09-09 2010-03-11 F. Hoffmann-La Roche Ag 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
GB0329362D0 (en) * 2003-12-18 2004-01-21 Glaxo Group Ltd Compounds
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
ES2406085T3 (es) * 2006-06-22 2013-06-05 F. Hoffmann-La Roche Ag Derivados de fenil-metanona sustituida y su empleo como inhibidores de receptores de GlyT1 y GlyT2

Also Published As

Publication number Publication date
DE602006007682D1 (de) 2009-08-20
CN101141959A (zh) 2008-03-12
WO2006077026A1 (en) 2006-07-27
ES2326833T3 (es) 2009-10-20
US20060160788A1 (en) 2006-07-20
IL184439A (en) 2011-11-30
US7790763B2 (en) 2010-09-07
AU2006207650A1 (en) 2006-07-27
EP1843767B1 (en) 2009-07-08
ATE435650T1 (de) 2009-07-15
KR20070094971A (ko) 2007-09-27
JP2008527016A (ja) 2008-07-24
CA2601326A1 (en) 2006-07-27
AU2006207650B2 (en) 2011-01-27
EP1843767A1 (en) 2007-10-17
MX2007008616A (es) 2007-09-11
KR100935256B1 (ko) 2010-01-06
IL184439A0 (en) 2007-10-31
CN101141959B (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
EA200901373A1 (ru) Аминогетероциклические соединения
ATE438632T1 (de) Aryl-4-ethinylisoxazolderivate
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
ATE473967T1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
IL189762A0 (en) Isoxazolo derivatives as gaba a alpha5 inverse agonists
IL190867A0 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
UA102236C2 (uk) Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування
DE602004008098T8 (de) Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
IL184439A0 (en) 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
EA200701758A1 (ru) Замещённые арильные производные 1,4-пиразина
ATE434605T1 (de) Inhibitoren des serotonintransporters (sert)
EA200970496A1 (ru) Соединения 2-алкилиндазола для лечения некоторых расстройств цнс
IL188109A0 (en) Chloro-substituted guanidines
ATE378339T1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
WO2007080159A3 (en) Pyridine-, isoxazole, thiophenecarboxamide compounds having activity at the glycine transporter glyt1 and uses thereof
DE602008005014D1 (de) Prolinamidtetrazolderivate als nk3-rezeptorantagonisten

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.